RESUMEN
The year 2023 was an extraordinary year for the further development and expansion of novel treatments for all patients with cervical cancer, ranging from early stage to later stage and metastatic or recurrent disease. Individuals with early-stage disease will benefit from less invasive surgery with subsequent improvement in quality of life. The effectiveness of immunotherapy has been demonstrated in upfront, locally advanced cervical cancer and confirmed in advanced metastatic disease. Induction chemotherapy will play a role in some patients with locally advanced disease, particularly those in low resource areas of the world. Novel therapeutics including antibody-drug conjugates have shown efficacy even in pretreated patients. As we continue to explore innovative therapeutics in this space, however, we must also continue to improve the diversity of clinical trial accrual to allow for generalizable results. At the same time, we must focus on eradicating this disease with appropriate screening and vaccination.
Asunto(s)
Inmunoterapia , Neoplasias del Cuello Uterino , Humanos , Neoplasias del Cuello Uterino/terapia , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/tratamiento farmacológico , Femenino , Inmunoterapia/métodos , Calidad de Vida , Estadificación de Neoplasias , Quimioterapia de InducciónRESUMEN
â¢Metastatic disease to the small bowel may present with intussusception.â¢Clinical decision making for malignant bowel obstruction is difficult and individual specific.â¢Malignant bowel obstruction due to metastatic year has an average life expectancy of less than 200 days.